Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03405662 · ClinicalTrials.gov registry record · NA
Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT03405662 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 23 participants.
The verdict
NCT03405662, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
Photobiomodulation (PBM) describes the use of near-infrared light (which is not visible to the eye) to heal and protect tissue that has either been injured, is degenerating, or else is at risk of dying. Research suggests that the light delivered during PBM enhances the body's biochemical ability to store and use energy and increase blood flow, which triggers the body's natural healing processes. The primary goal of this study is to determine if PBM administered transcranially (through the scalp and skull) and intranasally (inside the nose) with a commercially available device is safe and tolerable for patients with mild-to-moderate Alzheimer's disease (AD). Secondary goals are to examine whether tPBM has an effect on cognitive function and behavioral symptoms in patients with AD and whether tPBM has an effect on fluid biomarkers of AD. A biomarker is a specific physical trait used to measure the progress of a disease or condition.
Interventions
- DEVICE Vielight Neuro Gamma
- OTHER Sham Vielight Neuro Gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-08-16 |
| Est. Completion | 2021-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03405662
The ClinicalTrials.gov registry entry for NCT03405662 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vielight Neuro Gamma is the first listed.
NCT03405662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03405662 about?
NCT03405662 is a clinical study titled "Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease". Photobiomodulation (PBM) describes the use of near-infrared light (which is not visible to the eye) to heal and protect tissue that has either been injured, is degenerating, or else is at risk of dying. Research suggests that the light delivered during PBM enhances the body's biochemical ability to ...
What is the current status of trial NCT03405662?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2018-08-16. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT03405662?
The interventions under investigation include: Vielight Neuro Gamma (DEVICE), Sham Vielight Neuro Gamma (OTHER).
Who is sponsoring clinical trial NCT03405662?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.